1995
DOI: 10.1111/j.1749-6632.1995.tb31376.x
|View full text |Cite
|
Sign up to set email alerts
|

Responses to Pure Antiestrogens (ICI 164384, ICI182780) in Estrogen‐Sensitive and‐Resistant Experimental and Clinical Breast Cancera

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

2
42
2
1

Year Published

1998
1998
2021
2021

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 81 publications
(47 citation statements)
references
References 33 publications
2
42
2
1
Order By: Relevance
“…In vitro, fulvestrant significantly decreased ER protein levels and inhibited PgR expression in MCF-7 cells (McClelland et al 1996). In contrast, tamoxifen increased MCF-7 ER (oestrogen withdrawal has a similar effect) and PgR protein levels (Horowitz & McGuire 1978, Nicholson et al 1995, Early Breast Cancer Trialists' Collaborative Group 1998, Hutcheson et al 2003. In vivo, a single 5 mg dose of fulvestrant (short-acting formulation) was as effective as tamoxifen (10 mg/kg/day orally) in blocking the growth of MCF-7 xenografts in nude mice (Wakeling et al 1991).…”
Section: Biological Effects Of Pure Oestrogen Antagonistsmentioning
confidence: 99%
“…In vitro, fulvestrant significantly decreased ER protein levels and inhibited PgR expression in MCF-7 cells (McClelland et al 1996). In contrast, tamoxifen increased MCF-7 ER (oestrogen withdrawal has a similar effect) and PgR protein levels (Horowitz & McGuire 1978, Nicholson et al 1995, Early Breast Cancer Trialists' Collaborative Group 1998, Hutcheson et al 2003. In vivo, a single 5 mg dose of fulvestrant (short-acting formulation) was as effective as tamoxifen (10 mg/kg/day orally) in blocking the growth of MCF-7 xenografts in nude mice (Wakeling et al 1991).…”
Section: Biological Effects Of Pure Oestrogen Antagonistsmentioning
confidence: 99%
“…Fulvestrant does not produce conformational changes in the ER that elicit DNA or coactivator binding or AF-1 and AF-2 activation and lacks estrogen agonist activity in a wide range of tissue, cell, and promoter contexts (McDonnell et al, 2002;Osborne et al, 2004). Fulvestrant also decreases ER␣ levels in breast cancer cells by alterations in ER trafficking that hasten proteolytic degradation (Nicholson et al, 1995;Wittmann et al, 2007) and is thus considered a selective estrogen receptor downregulator. The small ligand-binding cavity of ERR␥ is ill-suited for the bulky steroid nucleus and side chain of fulvestrant (Greschik et al, 2002(Greschik et al, , 2004, and high-throughput ligand discovery efforts have not identified fulvestrant as an ERR␥ ligand (Coward et al, 2001;Tremblay et al, 2001).…”
Section: Introductionmentioning
confidence: 99%
“…ICI 182,780 (ICI, fulvestrant, Faslodex) is an estrogen receptor antagonist, as binding to ERα causes a conformational change disabling both AF-1 and AF-2. Furthermore, the ICI-ERα complex is unstable, resulting in accelerated degradation of the ERα protein (20). ICI is used as an adjuvant endocrine therapy to treat ER-positive metastatic breast cancers in postmenopausal women with disease progression following the first line of antiestrogen therapy, as tamoxifen-as well as aromatase-resistant tumors might remain sensitive to ICI treatment (21).…”
mentioning
confidence: 99%